FDA declines to approve Cosmo’s NDA for Methylene Blue MMX
The CRL is consistent with the preliminary feedback Cosmo announced on May 9, 2018, stating that the FDA identified unspecified deficiencies that preclude the continuation of the discussion
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and milestone payments.
The patents, among other aspects, broadly cover compositions of matter of the inflammation-targeting microfiber materials with embedded molecules of interest. The platform is being evaluated for use across